238 related articles for article (PubMed ID: 26356818)
21. The relationship of cytomorphology of medullary thyroid carcinomas between family members with the same RET proto-oncogene mutation.
Chang JS; Chang CF; Yang WS; Chang TC
Acta Cytol; 2011; 55(6):556-62. PubMed ID: 22156466
[TBL] [Abstract][Full Text] [Related]
22. Dermal Hyperneury and Multiple Sclerotic Fibromas in Multiple Endocrine Neoplasia Type 2A Syndrome.
Alegría-Landa V; Jo-Velasco M; Robledo M; Requena L
JAMA Dermatol; 2017 Dec; 153(12):1298-1301. PubMed ID: 29049491
[TBL] [Abstract][Full Text] [Related]
23. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form.
Figlioli G; Landi S; Romei C; Elisei R; Gemignani F
Mutat Res; 2013; 752(1):36-44. PubMed ID: 23059849
[TBL] [Abstract][Full Text] [Related]
24. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
[TBL] [Abstract][Full Text] [Related]
25. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
26. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A.
Schulte KM; Machens A; Fugazzola L; McGregor A; Diaz-Cano S; Izatt L; Aylwin S; Talat N; Beck-Peccoz P; Dralle H
J Clin Endocrinol Metab; 2010 Sep; 95(9):E92-7. PubMed ID: 20554711
[TBL] [Abstract][Full Text] [Related]
27. Medullary Thyroid Carcinoma Associated with Germline RET
Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
[TBL] [Abstract][Full Text] [Related]
28. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
[TBL] [Abstract][Full Text] [Related]
29. RET codon 618 mutations in Saudi families with multiple endocrine neoplasia Type 2A and familial medullary thyroid carcinoma.
Qari F
Ann Saudi Med; 2013; 33(2):155-8. PubMed ID: 23563004
[TBL] [Abstract][Full Text] [Related]
30. RET gene mutations and polymorphisms in medullary thyroid carcinomas in Indian patients.
Sharma BP; Saranath D
J Biosci; 2011 Sep; 36(4):603-11. PubMed ID: 21857107
[TBL] [Abstract][Full Text] [Related]
31.
Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ
Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476
[No Abstract] [Full Text] [Related]
32. Genotype-specific progression of hereditary medullary thyroid cancer.
Machens A; Lorenz K; Weber F; Dralle H
Hum Mutat; 2018 Jun; 39(6):860-869. PubMed ID: 29656518
[TBL] [Abstract][Full Text] [Related]
33. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
[TBL] [Abstract][Full Text] [Related]
34. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Krampitz GW; Norton JA
Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
[TBL] [Abstract][Full Text] [Related]
35. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
36. Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium.
Machens A; Lorenz K; Sekulla C; Höppner W; Frank-Raue K; Raue F; Dralle H
Eur J Endocrinol; 2013 Mar; 168(3):307-14. PubMed ID: 23211574
[TBL] [Abstract][Full Text] [Related]
37. Frequent association between MEN 2A and cutaneous lichen amyloidosis.
Verga U; Fugazzola L; Cambiaghi S; Pritelli C; Alessi E; Cortelazzi D; Gangi E; Beck-Peccoz P
Clin Endocrinol (Oxf); 2003 Aug; 59(2):156-61. PubMed ID: 12864791
[TBL] [Abstract][Full Text] [Related]
38. Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family.
Basaran MN; Tuna MM; Karakılıç E; Doğan BA; İmga NN; Berker D; Güler S
J Endocrinol Invest; 2015 May; 38(5):541-6. PubMed ID: 25501606
[TBL] [Abstract][Full Text] [Related]
39. The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A.
Yang Z; Qi X; Gross N; Kou X; Bai Y; Feng Y; Wang B; Zafereo ME; Li G; Sun C; Li H; Chen X; Huang Z
J Cell Mol Med; 2020 Nov; 24(22):13163-13170. PubMed ID: 32989896
[TBL] [Abstract][Full Text] [Related]
40. Current understanding and management of medullary thyroid cancer.
Roy M; Chen H; Sippel RS
Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
